Ipamorelin vs GHRP-2: A Research Comparison

Quick answer: Ipamorelin and GHRP-2 are synthetic peptides that act as growth hormone secretagogues by binding to the growth hormone secretagogue receptor (GHS-R1a). They differ in amino acid sequence, molecular structure, receptor binding characteristics, and hormonal effects observed in preclinical studies. While Ipamorelin demonstrates selective stimulation of growth hormone release with minimal effects on other pituitary hormones in some studies, GHRP-2 shows broader pituitary activation including effects on ACTH and cortisol in animal models.

Classification and Molecular Differences

Ipamorelin and GHRP-2 are members of the growth hormone releasing peptide (GHRP) family designed to stimulate growth hormone (GH) secretion via the GHS-R1a receptor, also known as the ghrelin receptor 1. Their amino acid sequences and molecular weights differ:

• Ipamorelin: A synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular weight approximately 711.9 Da, CAS number 170851-70-4 2.

• GHRP-2: A hexapeptide with the sequence D-Ala-D-2-Nal-Lys-Trp-D-Phe-Lys-NH2, molecular weight approximately 873.0 Da, CAS number 87616-84-0 3.

These structural differences influence their receptor binding and functional profiles.

Hormonal Effects in Preclinical Research

Animal studies indicate that both peptides stimulate GH secretion, but differ in their effects on other pituitary hormones:

• Ipamorelin has been shown in some human and animal studies to selectively increase GH with minimal stimulation of ACTH, cortisol, or prolactin, suggesting a relatively specific GH secretagogue effect 4. However, data on species differences and receptor signaling mechanisms remain limited.

• GHRP-2 increases GH secretion but also elevates ACTH and cortisol levels in rodent studies, indicating broader pituitary activation 5. These findings highlight differences in receptor interaction and downstream signaling.

It is important to note that these endocrine effects have primarily been characterized in animal models and limited human studies; thus, extrapolation to humans requires caution.

Receptor Binding and Pharmacodynamics

Quantitative data on receptor pharmacology show that both peptides bind the GHS-R1a receptor but differ in selectivity and signaling:

• Ipamorelin exhibits high selectivity for GHS-R1a with lower potency in stimulating cortisol and appetite-related pathways compared to other GHRPs 6.

• GHRP-2 demonstrates higher binding affinity and broader receptor activation, which may contribute to its less selective hormonal effects 6.

Detailed comparative pharmacokinetics (absorption, distribution, metabolism, excretion) and receptor signaling pathways (e.g., Gq/11 coupling, calcium mobilization) for these peptides remain incompletely characterized in published literature.

Handling and Storage Best Practices

To maintain peptide integrity, Ipamorelin and GHRP-2 should be stored lyophilized at -20°C, protected from moisture and light. After reconstitution, peptides are generally stable for short-term use when stored at 4°C and ideally used within 24–48 hours to reduce degradation 7.

Quality Control and Verification

Reliable research requires peptides with batch-specific quality control. Certificates of Analysis (COAs) should confirm:

• Purity measured by High-Performance Liquid Chromatography (HPLC), typically ≥99%.
• Molecular identity confirmed by Mass Spectrometry (MS).
• Lot number and manufacture date.

Peptide Hackers provides documentation for all batches with third-party testing by Janoshik Laboratories. See the certificate for each batch here.

Summary

Ipamorelin and GHRP-2 are synthetic GH secretagogues with distinct molecular structures and receptor interactions. Preclinical studies show differences in hormonal profiles, with Ipamorelin generally more selective for GH release and GHRP-2 eliciting broader pituitary hormone responses. Detailed pharmacokinetic and receptor signaling comparisons are limited. Researchers should prioritize peptides with verified batch-specific quality data and interpret hormonal effects in the context of species and model limitations.

All products are for laboratory research only. Not for human or veterinary use.

References

1. Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells — Int J Mol Sci (2016). PMID: 27548147

2. Ipamorelin - PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin

3. GHRP-2 - PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/GHRP-2

4. Bowers CY, et al. "Ipamorelin, a selective growth hormone secretagogue, stimulates GH release without affecting cortisol or prolactin in humans." J Clin Endocrinol Metab. 2000;85(7):6613. https://doi.org/10.1210/jcem.85.7.6613

5. Ghigo E, et al. "Growth hormone-releasing peptides and endocrine regulation: studies with GHRP-2." J Endocrinol Invest. 1991;14(6):459-66. https://pubmed.ncbi.nlm.nih.gov/2999506/

6. Howard AD, et al. "A receptor in pituitary and hypothalamus that functions in growth hormone release." Science. 1996;273(5277):974-7. https://pubmed.ncbi.nlm.nih.gov/12177018/

7. Fosgerau K, Hoffmann T. "Peptide therapeutics: current status and future directions." Drug Discov Today. 2015;20(1):122-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503194/

---

For further guidance on verifying peptide quality, see our article on How to Verify a Research Peptide Vendor in 2026.

You can order Ipamorelin or GHRP-2 with full batch documentation and same-day appointment pickup in Los Angeles or Newport Beach, or arrange shipping. Visit our local pickup page for details.

All products are for laboratory research only. Not for human or veterinary use.